CATX Perspective Therapeutics, Inc.

8-K Current Report

Filed: March 16, 2026

Health Care

Pharmaceutical Preparations

Perspective Therapeutics, Inc. (CATX) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Full-year 2025 financial results announced March 16, 2026 — details in Exhibit 99.1
• CATX is a clinical-stage radiopharmaceutical company; annual results signal cash runway and pipeline spending pace

Item 8.01 · Other Events

• Press release and corporate presentation filed March 16, 2026 — content not disclosed in filing text; refer to Exhibit 99.1 and 99.2 for material details
• CFO Joel Sendek signed the filing, confirming executive authorization

+1 more insights

Get deeper insights on Perspective Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.